Causal Inference Questions

Direct answer. With concurrent experiments and launches, isolate your model's specific contribution by using a design that holds the OTHER changes constant for at least part of your comparison, either through factorial/orthogonal experiment assignment (so your treatment and the other experiments are statistically independent of each other) or through instrumentation that logs exactly which users were exposed to which concurrent treatments, letting you control for them explicitly in the analysis.

Structured elaboration.

1. Experimental design, ideally set up in advance: factorial designs, where your model's rollout and other concurrent experiments are randomized INDEPENDENTLY of each other, are the cleanest solution, since independence guarantees no correlation between your treatment and the other launches to worry about. If you don't control the other experiments' design, the next-best option is comprehensive exposure logging: know, for every user, exactly which concurrent treatments they were exposed to.
2. Instrumentation: log treatment assignment for every concurrent experiment at the user level, not just aggregate rollout percentages, so you can include them as controls (or interaction terms, if you suspect the effects aren't simply additive) in your analysis.
3. Handling interference retroactively, if the design wasn't set up cleanly in advance: include the other experiments' assignment indicators as covariates in a regression alongside your own treatment indicator; check whether your estimated effect is stable when you add or remove these controls (a large swing signals real interference you need to account for, a stable estimate is reassuring).

Worked example. Your personalization model rolled out to 20% of users while two other experiments (a pricing test and a UI redesign) were also running on overlapping populations. If exposure logs show the three experiments were independently randomized (a factorial design), regressing revenue on all three treatment indicators simultaneously cleanly separates your model's own coefficient from the other two, since independence means the coefficient doesn't move much whether or not the other two are included. If instead the UI redesign happened to be biased toward the SAME users your model targeted (correlated, not independent, assignment), you'd see your model's estimated effect shift noticeably depending on whether the UI redesign indicator is included, a direct symptom of the interference you'd otherwise miss.

Trade-offs and pitfalls. The costliest mistake is assuming independence without checking it; two experiments that were each individually randomized can still end up correlated in practice if, for example, both preferentially targeted engaged users or the same geographic rollout order, and that correlation is exactly what breaks the clean-attribution logic silently.

Direct answer. Simpson's paradox is when an association between two variables reverses direction once you stratify (split) the data by a third variable, compared to the direction it showed in the aggregated data. It happens because the aggregate mixes groups of very different sizes and rates in a way that the overall average can hide, or even invert, what's true within every individual group.

Structured elaboration and worked example. Suppose you're comparing conversion rate for a checkout redesign, variant A versus variant B, across two customer segments:

Within every single segment, A has the higher conversion rate (93.1% beats 86.7% for returning customers; 73.0% beats 68.8% for new customers). Yet in the aggregate, B looks better (82.6% beats 78.0%). The mechanism is segment mix, not a real reversal of effect: returning customers convert far more easily than new customers regardless of variant, and B happened to be shown to returning customers 270 times but new customers only 80 times, while A was shown to returning customers only 87 times but new customers 263 times. B's aggregate number is inflated because it was tested overwhelmingly on the easier segment, not because it's the better variant. Stratifying by segment and comparing within each one separately, rather than trusting the unstratified aggregate, is what reveals that A is actually the consistently better performer.

Trade-offs and pitfalls. Simpson's paradox is not a data-quality bug, it's a structural consequence of unequal group sizes and unequal rates across groups, so the fix is never "clean the data harder"; it's always "check whether the segment mix differs between the groups you're comparing before trusting an aggregate.

Direct answer. Whether the 8% US engagement lift should transport to other markets depends on whether the mechanism driving the effect is likely to be similar elsewhere, not just on the fact that the experiment was well-run; the practical recommendation is a smaller-scale, faster confirmatory test in one or two representative non-US markets before a full global rollout, rather than either blindly extrapolating or re-running the full US-scale experiment everywhere.

Structured elaboration. External validity concerns to check before trusting the transport: does the recommendation algorithm rely on signals (content catalog density, user behavior patterns) that differ meaningfully across markets? Are user demographics, device mix, or competitive landscape different enough that the mechanism behind the 8% lift might not hold? Is there a reason the US result itself might be inflated or unusual (a novelty effect specific to the timing of the US test, a US-specific promotional overlap)? None of these can be answered from the US experiment alone; they require either domain knowledge about the mechanism or additional data from the target markets.

Worked example. If the recommendation algorithm's lift came largely from surfacing under-explored long-tail content, and a target market has a much smaller content catalog, the mechanism plausibly weakens there, and blind rollout risks a much smaller (or even negative, if the algorithm's other trade-offs dominate without a large content pool to draw on) effect. A quick, cheap way to get real signal without a full-scale re-test: run a smaller, shorter experiment in one or two representative non-US markets, sized to detect a materially smaller effect than 8% (say, powered to detect 3%), which is enough to catch a "doesn't transport" result without the cost of a full re-test everywhere.

Trade-offs and pitfalls. The two extreme responses, "the randomized controlled trial (RCT) proved it works, roll out everywhere" and "every market is different, re-run the full experiment everywhere," are both wrong for different reasons: the first ignores that external validity is a real, checkable risk, not a formality, and the second is often needlessly slow and expensive when a smaller confirmatory test in a few representative markets would resolve most of the uncertainty at a fraction of the cost. Multi-country experiment designs that stratify by market characteristics upfront (rather than testing one market at a time sequentially) are the more scalable version of this same logic when you're rolling out across many markets at once.

Direct answer. Causal forests and double/debiased machine learning (DML) both use flexible machine-learning models to estimate causal effects while avoiding the bias that naively plugging ML predictions into a causal estimate would introduce; causal forests directly target heterogeneous treatment effects (a tree-based method that splits on covariates specifically to maximize detected treatment-effect heterogeneity), while DML more generally uses ML models for nuisance functions (the propensity and outcome models) combined with an orthogonalized estimating equation that's robust to moderate errors in those nuisance models.

Structured elaboration. The key theoretical idea behind DML is Neyman orthogonality: constructing the estimating equation so that its sensitivity to SMALL errors in the nuisance function estimates is zero to first order, which is why flexible, regularized ML models (which have some estimation error by construction) can still be plugged in without that error directly biasing the causal estimate, as long as cross-fitting is used (fitting nuisance models on one fold, evaluating the causal estimate on a held-out fold) to prevent the same data from both fitting and evaluating the nuisance models.

Identification assumptions. Both methods still rely on the same fundamental assumptions as any observational causal estimate: unconfoundedness (all relevant confounders are measured and included as covariates) and overlap (every unit has a non-zero, non-one probability of treatment given its covariates); flexible ML modeling improves how well you can estimate the NUISANCE functions given the covariates you have, but it does nothing to address an unmeasured confounder that was never captured in the data at all.

Practical tuning and interpretation considerations. Causal forests need enough data per "leaf" (terminal split) to estimate a treatment effect reliably within it, which limits how fine-grained the heterogeneity detection can be with a modest sample; honest splitting (using separate subsamples to determine the tree structure versus to estimate effects within it) is what protects against the model finding spurious subgroup effects purely from overfitting the same data twice. Cross-fitting and sample splitting generally cost some statistical efficiency (using less data per step) in exchange for this robustness, a trade-off that's usually worth it once you're using flexible enough models that overfitting is a real risk.

Trade-offs and pitfalls. These methods are frequently mistaken for a way to "solve" confounding through modeling sophistication; they don't relax the unconfoundedness assumption at all, they only make the NUISANCE-function estimation step more flexible and less bias-prone than a naive plug-in approach, which is a meaningfully narrower (though still valuable) claim than ‘machine learning fixes causal inference.’

Direct answer. Check overlap (also called common support) by comparing the distributions of propensity scores between the treated and control groups. If both groups span a similar range of scores, with enough control units near every treated unit's score and vice versa, comparisons are trustworthy. If treated units cluster at scores where almost no control units exist (or the reverse), the propensity model is effectively extrapolating, and the resulting comparison isn't supported by real data.

Structured elaboration. Two practical checks: (1) plot the propensity score distributions for both groups on the same axis and visually inspect where they do and don't overlap; (2) after matching, report how many treated units were dropped for lack of a close enough control match (a high drop rate is itself a symptom of poor overlap). A stricter numeric check is to look at the propensity score range where both groups have reasonable density, sometimes trimmed to, say, the 5th to 95th percentile of the overlapping region, and restrict the analysis to that region rather than the full sample.

Worked example. Suppose you're comparing users who enabled a feature (treated) against those who didn't (control) using a propensity model built from tenure and engagement. If nearly all treated users have propensity scores between 0.6 and 0.95, but 90% of control users have scores under 0.3, only a thin sliver of control users (those with scores above 0.6) is actually comparable to the treated group; the average treatment effect on the treated (ATT) estimate would then only be credible for that sliver, not for the typical treated user.

Trade-offs and pitfalls. It's tempting to fix poor overlap by widening the caliper or accepting worse matches, but that just trades an honest "we can't estimate this for the full population" for a quietly biased estimate. The more defensible response is to redefine the estimand (report the ATT only for the region of common support, and say so explicitly) or collect more data in the poorly-overlapped region.